Navigation Links
BioPharmX Corporation Closes Direct Investment
Date:12/10/2015

MENLO PARK, Calif., Dec. 10, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the closing of a direct investment of approximately $5.9 million through the sale of 4,100,000 shares of the Company's common stock at a purchase price of $1.43 per share to investment vehicles of Franklin Advisers.

"This investment is an important recognition of the value that our pipeline promises and will help us accelerate our efforts to fulfill the unmet medical and wellness needs of patients," said Jim Pekarsky, BioPharmX CEO. "It will support our Violet marketing programs, facilitate clinical trials for our topical acne treatment and help us advance additional pipeline initiatives." 

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within three months of the closing for purposes of registering the resale of the shares of common stock issued in the private placement. CRT Capital Group LLC acted as a financial advisor to the Company.

About BioPharmX™ Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those section. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding: the success of the commercialization of VI2OLET iodine, the successful advancement of the Company's product candidates and development pipeline and the expected use of proceeds from this offering. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. BioPharmX and Violet are registered trademarks of BioPharmX, Inc.

Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO

 


'/>"/>
SOURCE BioPharmX Corporation
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Study Shows BioPharmX Formulation Offers More Effective Acne Treatment by Targeted Delivery of Minocycline
2. Study Shows Novel BioPharmX Formulation Promises Breakthrough in Acne Treatment
3. BioPharmX Corporation Expands Management Team to Support Growth and Market Expansion
4. BioPharmX Corporation to Release Second Quarter 2016 Financial Results
5. BioPharmX Corporation To Present at Rodman & Renshaw 17th Annual Global Investment Conference
6. BioPharmX Corporation Launches #HugsShouldntHurt Social Media Campaign
7. BioPharmX To Ring New York Stock Exchange Opening Bell To Celebrate Its Listing On NYSE MKT
8. BioPharmX Corporation Closes Underwritten Public Offering of Common Stock
9. BioPharmX Corporation Files Registration Statement For Proposed Public Offering
10. BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors
11. BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
(Date:10/12/2017)... ... 12, 2017 , ... Nvision Biomedical Technologies , a ... addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice President of ... sales network, direct the efforts of the surgical sales teams, manage contractual agreements, ...
Breaking Medicine News(10 mins):